PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
PEA resulted in a significant reduction in pain scores at 1, 1.5, 2, and 2.5 hours post-administration [PMID:39910730]
Participants taking PEA reported fewer URTI episodes (39 vs 64) and a significant reduction in median severity scores for cough and scratchy throat [PMID:37892528]
Topical application of PEA was effective at alleviating the symptom severity of eczema [PMID:38408443]
PEA supplementation resolved more headaches after 2 and 8 hours and resulted in lower pain scores on the visual analogue scale at 1 hour [PMID:38399360]
No significant difference was seen between PEA and placebo in reducing symptoms of seasonal allergic rhinitis [PMID:38068797]
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 39910730 (2025) — Palmitoylethanolamide (Levagen+) for acute menstrual pain: a randomized, crossover, double-blind, placebo-controlled trial. · Women & health
- 2.PMID: 38790705 (2024) — Therapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders. · Antioxidants (Basel, Switzerland)
- 3.PMID: 24952959 (2014) — Harnessing the anti-inflammatory potential of palmitoylethanolamide. · Drug discovery today
- 4.PMID: 37892528 (2023) — The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial. · Nutrients
- 5.PMID: 38068797 (2023) — The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.